These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 67089

  • 41. Formation of high-affinity C5 convertases of the alternative pathway of complement.
    Rawal N, Pangburn M.
    J Immunol; 2001 Feb 15; 166(4):2635-42. PubMed ID: 11160326
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Activity of the alternative pathway of complement in the newborn infant.
    Adamkin D, Stitzel A, Urmson J, Farnett ML, Post E, Spitzer R.
    J Pediatr; 1978 Oct 15; 93(4):604-8. PubMed ID: 702236
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC.
    Kidney Int; 2017 Jun 15; 91(6):1386-1397. PubMed ID: 28139294
    [Abstract] [Full Text] [Related]

  • 48. Serum complement components in patients with trachoma.
    Sen DK, Sarin GS, Hiranandani M, Baveja UK.
    Br J Ophthalmol; 1985 Sep 15; 69(9):707-10. PubMed ID: 3876110
    [Abstract] [Full Text] [Related]

  • 49. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W, Schmidt G, Lynen R, Dieminger L.
    J Immunol; 1975 Feb 15; 114(2 Pt 1):671-7. PubMed ID: 804510
    [Abstract] [Full Text] [Related]

  • 50. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
    Nicholson A, Brade V, Lee GD, Shin HS, Mayer MM.
    J Immunol; 1974 Mar 15; 112(3):1115-23. PubMed ID: 4811964
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Participation of an early component of complement and Hageman factor in C3 destruction by zymosan.
    Gigli I, Koethe S, Austen KF.
    Clin Immunol Immunopathol; 1975 Jul 15; 4(2):189-98. PubMed ID: 1170051
    [No Abstract] [Full Text] [Related]

  • 53. Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway.
    Theofilopoulos AN, Perrin LH.
    Science; 1977 Mar 04; 195(4281):878-80. PubMed ID: 402691
    [Abstract] [Full Text] [Related]

  • 54. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation.
    Giclas PC, King TE, Baker SL, Russo J, Henson PM.
    Am Rev Respir Dis; 1987 Feb 04; 135(2):403-11. PubMed ID: 3643768
    [Abstract] [Full Text] [Related]

  • 55. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K, Schur PH, Ruddy S.
    J Clin Invest; 1976 Jun 04; 57(6):1554-63. PubMed ID: 819459
    [Abstract] [Full Text] [Related]

  • 56. The role of properdin in the alternate pathway of complement activation.
    Götze O, Müller-Eberhard HJ.
    J Exp Med; 1974 Jan 01; 139(1):44-57. PubMed ID: 4808709
    [Abstract] [Full Text] [Related]

  • 57. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F, Bravo García-Morato M, Nozal P, Garrido S, Tortajada A, Rodríguez de Córdoba S, López-Trascasa M.
    Clin Exp Immunol; 2016 Apr 01; 184(1):118-25. PubMed ID: 26660535
    [Abstract] [Full Text] [Related]

  • 58. Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.
    Freeley SJ, Popat RJ, Parmar K, Kolev M, Hunt BJ, Stover CM, Schwaeble W, Kemper C, Robson MG.
    J Pathol; 2016 Sep 01; 240(1):61-71. PubMed ID: 27235854
    [Abstract] [Full Text] [Related]

  • 59. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB, Watson L, Goodkofsky I, Alper CA, Lepow IH.
    J Immunol; 1976 Jan 01; 116(1):75-9. PubMed ID: 812917
    [Abstract] [Full Text] [Related]

  • 60. The human complement system.
    Volanakis JE.
    J Oral Pathol; 1975 Jan 01; 4(4):195-221. PubMed ID: 811779
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.